PMID- 26945424
OWN - NLM
STAT- MEDLINE
DCOM- 20160715
LR  - 20220410
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 95
IP  - 9
DP  - 2016 Mar
TI  - Systematic Review and Network Meta-Analysis of Randomized Controlled Trials: 
      Comparative Effectiveness and Safety of Direct-Acting Antiviral Agents for 
      Treatment-Naive Hepatitis C Genotype 1.
PG  - e3004
LID - 10.1097/MD.0000000000003004 [doi]
LID - e3004
AB  - All possible direct-acting antiviral agent (DAA) regimens for treatment-naive 
      hepatitis C genotype 1 were evaluated by many randomized controlled trials 
      (RCTs). However, the optimum regimen remains inconclusive. We aim to compare 
      interventions in terms of sustained virological response at 12 (SVR12) and 24 
      (SVR24) weeks after the end of treatment and adverse effects (AEs) (fatigue, 
      headache, nausea, insomnia). PubMed, Embase, and the Cochrane Library were 
      searched for RCTs until July 31, 2015. We estimated odds ratios (ORs) between 
      treatments on clinical outcomes. Twenty-two eligible RCTs were included. Compared 
      with peginterferon-ribavirin (PR), daclatasvir plus PR (OR 8.90, P < 0.001), 
      faldaprevir plus PR (OR 3.72, P < 0.001), simeprevir plus PR (OR 3.59, 
      P < 0.001), sofosbuvir plus PR (OR 4.69, P < 0.001) yield a significant effect in 
      improving SVR12. Consistently, simeprevir plus PR (OR 3.49, P < 0.001), 
      sofosbuvir plus PR (OR 4.51, P < 0.001), daclatasvir plus PR (OR 4.77, P < 0.001) 
      also improved the rates of SVR24 significantly compared with PR. With respect to 
      AEs, compared with PR, ledipasvir plus sofosbuvir plus PR (OR 2.13, P < 0.001) 
      confer a significant AE in nausea, whereas daclatasvir plus PR (OR 0.20, 
      P < 0.001 and OR 0.18, P < 0.001, respectively) lowered the incidence of fatigue 
      and nausea significantly when compared with ledipasvir plus sofosbuvir plus PR. 
      Daclatasvir plus PR was the most effective in SVR12 and SVR24, but caused an 
      increased AEs profile (headache and insomnia). Combined ledipasvir with 
      sofosbuvir or combination of PR was associated with higher incidence of fatigue 
      and nausea.
FAU - Zhu, Gui-Qi
AU  - Zhu GQ
AD  - From the Department of Infection and Liver Diseases, Liver Research Center, the 
      First Affiliated Hospital of Wenzhou Medical University (G-QZ, J-NZ, D-ZC, T-TZ, 
      K-QS, M-HZ), School of the First Clinical Medical Sciences, Wenzhou Medical 
      University, Wenzhou (G-QZ, J-NZ, T-TZ), Department of Infection Diseases, the 
      First Hospital of Jiaxing, Jiaxing (Z-LZ), Queen Mary Hospital, University of 
      Hong Kong, Hong Kong (D-ZC), and Institute of Hepatology (K-QS, M-HZ), Wenzhou 
      Medical University, Wenzhou, China.
FAU - Zou, Zhuo-Lin
AU  - Zou ZL
FAU - Zheng, Ji-Na
AU  - Zheng JN
FAU - Chen, Da-Zhi
AU  - Chen DZ
FAU - Zou, Tian-Tian
AU  - Zou TT
FAU - Shi, Ke-Qing
AU  - Shi KQ
FAU - Zheng, Ming-Hua
AU  - Zheng MH
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Antiviral Agents)
SB  - IM
MH  - Antiviral Agents/*therapeutic use
MH  - Comparative Effectiveness Research
MH  - Drug Therapy, Combination
MH  - Genotype
MH  - Hepacivirus/*genetics
MH  - Hepatitis C, Chronic/*drug therapy/virology
MH  - Humans
MH  - Odds Ratio
MH  - Randomized Controlled Trials as Topic
MH  - Treatment Outcome
PMC - PMC4782908
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2016/03/06 06:00
MHDA- 2016/07/16 06:00
PMCR- 2016/03/07
CRDT- 2016/03/06 06:00
PHST- 2016/03/06 06:00 [entrez]
PHST- 2016/03/06 06:00 [pubmed]
PHST- 2016/07/16 06:00 [medline]
PHST- 2016/03/07 00:00 [pmc-release]
AID - 00005792-201603010-00078 [pii]
AID - 10.1097/MD.0000000000003004 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2016 Mar;95(9):e3004. doi: 10.1097/MD.0000000000003004.